What happened
Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.3 billion（約4兆円）, up 5.6% operationally, with adjusted net earnings rising 5.7% to $7.1 billion（約1.1兆円）. The company introduced several connected MedTech platforms: CARTOSOUND SONATA (AI-powered cardiac imaging), THERMOCOOL SMARTTOUCH SF (dual-energy ablation system with FDA authorization), OTTAVA (table-integrated robotic surgery system), and announced plans for MONARCH for Urology.
Why it matters
Johnson & Johnson is building an integrated ecosystem linking medical devices, software, and clinical data to strengthen digital capabilities and clinical efficiency across its portfolio. CEO Joaquin Duato described OTTAVA as "one of the most significant MedTech innovations we will bring to market this decade," signaling the company's commitment to become a major participant in surgical robotics—a competitive area where differentiation through connected platforms and data-driven insights can support sustained growth.
What to watch
Management expects CARTOSOUND SONATA adoption to continue in the United States during the second half of 2026 as it responds to competitive pressure in pulsed field ablation. The company believes OTTAVA and MONARCH could contribute meaningfully to MedTech growth by the end of the decade. An investigational erdafitinib device for bladder cancer, designed to deliver medicine over three months (compared with INLEXZO's three-week delivery), is also under development and could extend the device-enabled approach to oncology care.
Summaries like this, in your inbox every morning.
Johnson & Johnson's second-quarter results reflect solid operational momentum—sales growth of 5.6% with Innovative Medicine delivering 6.8% growth—but the company's strategic emphasis on connected MedTech platforms signals a deeper shift in how it plans to compete. The introduction of CARTOSOUND SONATA, THERMOCOOL SMARTTOUCH SF, OTTAVA, and the planned MONARCH for Urology are not isolated product launches; they represent a deliberate strategy to create an integrated digital ecosystem that links hardware, software, and clinical data. CEO Duato's characterization of OTTAVA as "one of the most significant MedTech innovations we will bring to market this decade" underscores management's confidence that surgical robotics—combined with data-driven insights from an open digital platform—can drive substantial revenue growth.
The competitive context matters: CARTOSOUND SONATA is explicitly positioned to respond to competitive pressure in pulsed field ablation, while THERMOCOOL SMARTTOUCH SF's dual-energy capability allows physicians to choose the right tool for each procedure, potentially reducing reliance on separate systems. The device-enabled oncology approach—exemplified by the three-month erdafitinib device versus the three-week INLEXZO—extends this logic beyond surgery into medical delivery, suggesting J&J believes connected, data-informed platforms can address fragmentation across the healthcare system and create durable competitive advantages.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Chunghwa Telecom president Rong-shy Lin said the shift from conversational AI to autonomous AI agents is resha…
CoreWeave fell 5% in premarket trading Friday and was on track to finish the week down 15%, after rebounding f…
Apple and Meta said they would jointly release a new open-weight AI model designed to run on high-end Macs, ai…
Investors put $38.5 billion into Asian startups in Q3, per Crunchbase data
A longtime Anthropic investor told Fortune he expects shares priced around $1.8 trillion, below the company's…
In Q2, billionaires or their funds sold six 'Magnificent Seven' AI stocks
